시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 RS 바이러스 백신 시장 보고서 : 역학, 파이프라인 분석, 시장 인사이트 및 예측(2025년)
Respiratory Syncytial Virus Vaccine Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts
상품코드 : 1763113
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

RS 바이러스 백신 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 7%로 성장할 전망이며, 18억 2,840만 달러로 성장이 예측됩니다. 이 예측 기간의 성장은 승인된 백신의 도입, 세계의 예방 접종 프로그램, 고령자의 증가, 헬스케어 인프라의 성장 등에 기인하고 있습니다. 예측 기간 주요 동향으로는 기술적 진보, 디지털 모니터링 도구, 개별화 백신, 혼합 백신 개발, 아주반트 혁신 등을 들 수 있습니다.

호흡기 감염의 유행 증가는 RS 바이러스 백신 시장의 성장을 가속할 것으로 예측됩니다. 호흡기 감염병은 부비동, 인두, 기도, 폐 등의 호흡기 계통을 침범하는 바이러스나 세균을 포함한 다양한 병원체에 의해 발생되는 질환입니다. 이러한 감염병의 이환율 상승 요인으로는 대기오염, 기후변화, 도시화, 고령화, 약제 내성 병원체의 출현 등을 들 수 있습니다. RS 바이러스 백신은 특히 영유아나 노인과 같은 감염되기 쉬운 집단에서 RS 바이러스 관련 질환을 예방함으로써 감염병 발생률을 낮추는 데 도움이 됩니다. 예를 들어, 영국 건강안보국은 2024년 10월 잉글랜드의 결핵 환자가 2022-2023년 10.7% 증가했으며, 4,380명에서 4,850명으로 증가했다고 보고했습니다. 이러한 호흡기 감염병의 이환율 증가는 RS 바이러스 백신 시장의 확대를 가속화시킬 것으로 예상됩니다.

RS 바이러스 백신 시장의 주요 동향은 백신 기술의 진보, 특히 재조합 단백질을 기반으로 한 기술의 이용에 주목을 받고 있다는 것입니다. 이 기술에는 면역 반응을 자극하는 백신을 만들기 위한 단백질의 유전자 변형이 포함됩니다. 예를 들어, 2023년 5월 영국 제약회사 GlaxoSmithKline은 60세 이상의 RS 바이러스에 의한 하기도 질환을 예방하기 위해 특별히 설계된 첫 RS 바이러스 백신인 Arexvy의 승인을 미국 식품의약국(FDA)으로부터 취득했습니다. AREXVY는, 재조합 단백질 베이스의 기술을 이용해, 바이러스가 인간 세포에 감염하는데 중요한 RS 바이러스 융합(F) 단백질을 표적으로 하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 바이오의약품 시장에서의 제품 특성

제4장 시장 동향 및 전략

제5장 시장 : 금리, 인플레이션, 지정학적 요인, 신형 코로나와 그 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제6장 세계의 성장 분석 및 전략 분석 프레임워크

제7장 세계의 가격 분석 및 예측

제8장 시장 세분화

제9장 세계의 임상적응증 역학

제10장 지역별 및 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 경쟁 구도 및 기업 프로파일

제29장 세계 시장 : 파이프라인 분석

제30장 세계 시장 경쟁 벤치마킹 및 대시보드

제31장 주요 인수합병(M&A)

제32장 최근 시장 동향

제33장 시장의 잠재력이 높은 국가, 부문 및 전략

제34장 부록

AJY
영문 목차

영문목차

A respiratory syncytial virus (RSV) vaccine is a medical preparation aimed at protecting individuals, especially infants, older adults, and high-risk groups, from severe respiratory infections caused by RSV. It functions by stimulating the immune system to recognize and combat the virus, thus lowering the risk of hospitalization and severe illness.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of RSV vaccines include viral vaccines, bacterial vaccines, and combination vaccines. A viral vaccine is specifically designed to prevent infections caused by viruses. It covers various indications, including those for pediatric, geriatric, and high-risk populations, and is distributed through hospitals, pharmacies, and government suppliers.

The respiratory syncytial virus vaccines market research report is one of a series of new reports from The Business Research Company that provides respiratory syncytial virus vaccines market statistics, including respiratory syncytial virus vaccines industry global market size, regional shares, competitors with a respiratory syncytial virus vaccines market share, detailed respiratory syncytial virus vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory syncytial virus vaccines industry. This respiratory syncytial virus vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The respiratory syncytial virus vaccine market size is expected to see strong growth in the next few years. It will grow to $1,828.4 million in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to the introduction of approved vaccines, global immunization programs, a rising geriatric population, and a growing healthcare infrastructure. Major trends in the forecast period include technological advancements, digital monitoring tools, personalized vaccines, the development of combination vaccines, and adjuvant innovations.

The increasing prevalence of respiratory infections is expected to drive the growth of the respiratory syncytial virus (RSV) vaccine market. Respiratory infections are diseases caused by various pathogens, including viruses and bacteria, that affect the respiratory system, such as the sinuses, throat, airways, or lungs. Factors contributing to the rising incidence of these infections include air pollution, climate change, urbanization, an aging population, and the emergence of drug-resistant pathogens. The RSV vaccine helps reduce the incidence of infections by preventing RSV-related illnesses, particularly in vulnerable groups such as infants and the elderly. For example, the UK Health Security Agency reported in October 2024 that tuberculosis (TB) cases in England increased by 10.7% from 2022 to 2023, rising from 4,380 to 4,850 cases. This growing incidence of respiratory infections is expected to accelerate the RSV vaccine market's expansion.

A key trend in the RSV vaccine market is the increased focus on advancements in vaccine technology, particularly the use of recombinant protein-based technology. This technology involves the genetic engineering of proteins to create vaccines that stimulate an immune response. For example, in May 2023, GlaxoSmithKline plc, a UK-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Arexvy, the first RSV vaccine specifically designed to prevent lower respiratory tract disease caused by RSV in individuals aged 60 and older. Arexvy uses recombinant protein-based technology to target the RSV fusion (F) protein, which is critical to the virus's ability to infect human cells.

In February 2024, AstraZeneca PLC, a UK-based biopharmaceutical company, acquired Icosavax, Inc. for $1.1 billion. This acquisition strengthens AstraZeneca's pipeline of vaccines and immune therapies, with Icosavax's leading candidate, IVX-A12, targeting RSV and human metapneumovirus (hMPV), two key pathogens responsible for severe respiratory infections in high-risk groups such as the elderly and individuals with chronic conditions. Icosavax, a clinical-stage U.S.-based biopharmaceutical company, is actively developing an RSV vaccine with its lead candidate, IVX-A12.

Major companies operating in the respiratory syncytial virus vaccine market are Pfizer Inc., GlaxoSmithKline plc, and Moderna Inc.

North America was the largest region in the respiratory syncytial virus vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory syncytial virus vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the respiratory syncytial virus vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The respiratory syncytial virus vaccine market consists of sales of protein-based vaccines, mRNA vaccines, monoclonal antibodies, and live-attenuated vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Respiratory Syncytial Virus Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on respiratory syncytial virus vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for respiratory syncytial virus vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The respiratory syncytial virus vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Respiratory Syncytial Virus Vaccine Market Characteristics

3. Respiratory Syncytial Virus Vaccine Market Biologic Drug Characteristics

4. Respiratory Syncytial Virus Vaccine Market Trends And Strategies

5. Respiratory Syncytial Virus Vaccine Market -Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Respiratory Syncytial Virus Vaccine Growth Analysis And Strategic Analysis Framework

7. Global Respiratory Syncytial Virus Vaccine Pricing Analysis & Forecasts

8. Respiratory Syncytial Virus Vaccine Market Segmentation

9. Global Respiratory Syncytial Virus Vaccine Epidemiology Of Clinical Indications

10. Respiratory Syncytial Virus Vaccine Market Regional And Country Analysis

11. Asia-Pacific Respiratory Syncytial Virus Vaccine Market

12. China Respiratory Syncytial Virus Vaccine Market

13. India Respiratory Syncytial Virus Vaccine Market

14. Japan Respiratory Syncytial Virus Vaccine Market

15. Australia Respiratory Syncytial Virus Vaccine Market

16. South Korea Respiratory Syncytial Virus Vaccine Market

17. Western Europe Respiratory Syncytial Virus Vaccine Market

18. UK Respiratory Syncytial Virus Vaccine Market

19. Germany Respiratory Syncytial Virus Vaccine Market

20. France Respiratory Syncytial Virus Vaccine Market

21. Eastern Europe Respiratory Syncytial Virus Vaccine Market

22. North America Respiratory Syncytial Virus Vaccine Market

23. USA Respiratory Syncytial Virus Vaccine Market

24. Canada Respiratory Syncytial Virus Vaccine Market

25. South America Respiratory Syncytial Virus Vaccine Market

26. Middle East Respiratory Syncytial Virus Vaccine Market

27. Africa Respiratory Syncytial Virus Vaccine Market

28. Respiratory Syncytial Virus Vaccine Market Competitive Landscape And Company Profiles

29. Global Respiratory Syncytial Virus Vaccine Market Pipeline Analysis

30. Global Respiratory Syncytial Virus Vaccine Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Respiratory Syncytial Virus Vaccine Market

32. Recent Developments In The Respiratory Syncytial Virus Vaccine Market

33. Respiratory Syncytial Virus Vaccine Market High Potential Countries, Segments and Strategies

34. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기